Hydroxocobalamin.

Methionine synthase needs cobalamin and 5-methyltetrahydrofolate together to remethylate homocysteine. Without B12 the folate stays locked in its methyl form and cannot re-enter the cycle.

Folate and B12 meet at methionine synthase, the single point where the two vitamins depend on each other. Supplying folate alone leaves that step limited by cobalamin.

B12 recycles homocysteine to methionine while B6-dependent transsulfuration routes it to cysteine. Between them the two vitamins cover both ways out of that junction.

Methionine synthase reductase uses FAD to return the cobalamin cofactor to its active reduced state. Poor riboflavin status therefore limits how well hydroxocobalamin can be used once absorbed.

Hydroxocobalamin carries a hydroxyl group at the cobalt centre that is exchanged for a methyl or adenosyl group inside the cell. It fills the same requirement as any other B12 form, so intakes add to one total.

Adenosylcobalamin is one of the two coenzyme forms hydroxocobalamin is converted into, serving methylmalonyl-CoA mutase in mitochondria. They meet the same need from different starting points.

Betaine hands a methyl group to homocysteine through BHMT without needing cobalamin, covering the same step by an independent route in liver and kidney.

Large ascorbate concentrations reduce and destabilise the cobalt centre of cobalamins in solution, degrading them. Formulators keep a big vitamin C dose apart from B12 for this reason.

The cobalt centre of hydroxocobalamin binds nitric oxide avidly, forming nitrosocobalamin, which is settled pharmacology. That scavenging works against the nitric oxide signalling arginine is taken to support.

B12 and folate supply the DNA synthesis that marrow cells need to divide, while iron supplies the haemoglobin they fill with. One without the other leaves the process limited.

Biotin-dependent propionyl-CoA carboxylase produces methylmalonyl-CoA and the B12-dependent mutase converts it to succinyl-CoA. The two vitamins run in series through propionate metabolism.

Ileal uptake of the intrinsic factor and B12 complex through the cubilin receptor requires calcium at the membrane. Without it the complex is not internalised.

Methionine synthase uses methylcobalamin, one of the two active forms hydroxocobalamin is converted into, to transfer a methyl group from folate onto homocysteine and regenerate methionine. The reaction sits at the junction of the folate and methionine cycles. Cobalamin availability is what keeps that transfer running.

The hydroxyl group at the beta-axial position of hydroxocobalamin is readily displaced by thiols, and glutathione forms glutathionylcobalamin, an intermediate on the intracellular route to the two active coenzyme forms. This thiol reactivity is a defining chemical feature of the hydroxo form and is why it behaves differently in solution from cyanocobalamin. The interaction is chemical rather than a measured clinical pairing.

N-acetylcysteine supplies a free thiol that, like glutathione, can displace the hydroxyl ligand on cobalamin and form a thiolatocobalamin. In a co-formulated liquid this changes which cobalamin species is actually present in the bottle. It is a formulation and stability consideration more than a physiological one.

Adenosylcobalamin is the cofactor of methylmalonyl-CoA mutase, the step that carries propionyl-CoA from odd-chain fatty acid and branched-chain amino acid breakdown into the citric acid cycle. Carnitine moves those fatty acids into the mitochondrion in the first place, so the two act in sequence on the same carbon. Methylmalonic acid, the marker that rises when this step is limited, is a marker of cobalamin function and not an outcome.

Hydroxocobalamin binds nitric oxide avidly at the cobalt centre, forming nitrosylcobalamin, and this scavenging is well characterised in pharmacology. Dietary nitrate is taken specifically to raise nitric oxide availability, so the two point in opposite directions at that molecule. Whether ordinary oral doses of hydroxocobalamin do this measurably is not established, which is why the flag is mechanistic.

Citrulline is taken to raise arginine and therefore nitric oxide synthase output, and hydroxocobalamin binds nitric oxide at its cobalt centre. The two work against each other on the same molecule in principle. No study has quantified this at supplement doses, so it is flagged rather than quantified.

Garlic organosulfur compounds are hydrogen sulfide donors, and hydroxocobalamin reacts with hydrogen sulfide at the cobalt centre, a reaction well documented in the pharmacology literature. Co-administration therefore involves two agents with a direct chemical reaction between them. The practical significance at dietary garlic intakes has not been measured.

Spirulina and several algae carry pseudocobalamin, a corrinoid with a different lower ligand that binds human cobalamin transport proteins without serving as a cofactor for methionine synthase or methylmalonyl-CoA mutase. Occupying the carrier without doing the work makes it a competitor rather than a source. This matters most where spirulina is being counted on as a B12 source.

When cobalamin is supplied after a period of very low status, the resumption of rapid red cell production draws potassium into the newly forming cells and can lower serum potassium. This is a well-described monitoring point in clinical practice rather than a benefit pairing. It applies to correction of a marked deficit under supervision, not to ordinary maintenance dosing.

Gastric acid and pepsin release protein-bound cobalamin from food so haptocorrin can pick it up, and low gastric acidity is one of the recognised reasons food-bound cobalamin absorption falls. Cobalamin in a supplement is already free, so the acid step matters far less for a tablet than for a meal. That distinction is often blurred on labels.

Cysteine's free thiol displaces the hydroxyl ligand on hydroxocobalamin in the same way glutathione does, producing a thiolatocobalamin species. Cysteine is also the product of the transsulphuration branch that homocysteine enters when it is not remethylated by the cobalamin-dependent route. The two therefore meet both chemically and at the pathway level.